

The SKY study (Study of Parkinson's Early Stage) is a new approach to treating Parkinson's disease because it will look at the build-up of iron in certain regions of the brain among people with Parkinson's disease. It is not known whether this build-up of iron is causing harm to the brain cells, or whether removing it may improve the motor symptoms of this disease or slow its progress. The SKY clinical study aims to address these questions.

The purpose of the study: The goal of this study is to evaluate the effects of deferiprone, an iron-chelating drug, in patients with Parkinson's disease. (Iron chelation therapy is the removal of excess iron from the body with special drugs.) Participants will receive one of four different dosages of deferiprone or placebo, and will take the assigned study product twice a day for nine months. They will come back to the study site for assessments at Months 1, 2, 3, 4, 5, 6, and 9 and will need to have their blood count checked weekly, at either the study site or a local laboratory.

Some of the eligibility criteria:

- Male or female aged ≥ 18 to < 80 years
- Body weight ≥ 60 kg but ≤ 100 kg
- Parkinson's disease newly diagnosed in the past three years
- currently taking antiparkinsonian medication

Where the study will be conducted: Toronto Western Hospital

If interested in participating: Call 416-603-5800 x5234

For more information: FoxTrialFinder.org (Fox Trial Finder Trial ID #4412); ClinicalTrials.gov (Study ID # NCT0272884), or Skystudy.ca